Funding for Ph1/2So I'm no expert on funding negotiations going into a Ph1/2 trial. However, given the possibility of an FDA fast track approval, Roger White really needs to make this a priority and I believe he also knows this. A $20 million dollar figure has been thrown out there so let's assume that is accurate.
Theralase has often repeated that the trial is scheduled to begin in early 2015. For most of us that means 1st quarter of 2015 so only 6-9 months away. There is also a belief here that individual patient results could come very quickly. Since this is not a blinded randomized trial it has been suggested that Theralase could report results on say 10 of the 30 patients enrolled.
It becomes clear then that the only major logjam may be in the funding for the Ph1/2 trial.
Given the high potential for early, positive results, the funding must now be the primary objective.
it occurs to me that since bladder cancer is the most expensive to treat but it is only the 4th most common tumor, Therelase may be able to be a little more generous on their negotiations given that this would be a billion dollar drug for bladder cancer alone IF successful!